| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8723399 | Médecine des Maladies Métaboliques | 2018 | 5 Pages |
Abstract
The last 10 to 20 years have profoundly changed the landscape of type 2 diabetes, with major event (outcome) studies - mainly cardiovascular, now available, while there was nothing in 1998, and with the availability for clinicians of new antidiabetic treatments that have supplanted those previously available, sulfonylureas and human insulins. It is possible for the clinician in 2018, which was not the case in the past, to offer the patient a rational therapeutic choice, both of the target HbA1c to be achieved in each individual case, and the best medication to propose to obtain it on a validated scientific basis.
Related Topics
Health Sciences
Medicine and Dentistry
Endocrinology, Diabetes and Metabolism
Authors
B. Charbonnel,